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secretion before diagnosis of type 2 diabetes: an analysis 
from the Whitehall II study
Adam G Tabák, Markus Jokela, Tasnime N Akbaraly, Eric J Brunner, Mika Kivimäki,* Daniel R Witte*
Summary
Background Little is known about the timing of changes in glucose metabolism before occurrence of type 2 diabetes. 
We aimed to characterise trajectories of fasting and postload glucose, insulin sensitivity, and insulin secretion in 
individuals who develop type 2 diabetes.
Methods We analysed data from our prospective occupational cohort study (Whitehall II study) of 6538 (71% male 
and 91% white) British civil servants without diabetes mellitus at baseline. During a median follow-up period of 
9·7 years, 505 diabetes cases were diagnosed (49·1% on the basis of oral glucose tolerance test). We assessed 
retrospective trajectories of fasting and 2-h postload glucose, homoeostasis model assessment (HOMA) insulin 
sensitivity, and HOMA β-cell function from up to 13 years before diabetes diagnosis (diabetic group) or at the end of 
follow-up (non-diabetics).
Findings Multilevel models adjusted for age, sex, and ethnic origin conﬁ rmed that all metabolic measures followed 
linear trends in the group of non-diabetics (10 989 measurements), except for insulin secretion that did not change 
during follow-up. In the diabetic group (801 measurements), a linear increase in fasting glucose was followed by a 
steep quadratic increase (from 5·79 mmol/L to 7·40 mmol/L) starting 3 years before diagnosis of diabetes. 2-h postload 
glucose showed a rapid increase starting 3 years before diagnosis (from 7·60 mmol/L to 11·90 mmol/L), and HOMA 
insulin sensitivity decreased steeply during the 5 years before diagnosis (to 86·7%). HOMA β-cell function increased 
between years 4 and 3 before diagnosis (from 85·0% to 92·6%) and then decreased until diagnosis (to 62·4%).
Interpretation In this study, we show changes in glucose concentrations, insulin sensitivity, and insulin secretion as 
much as 3–6 years before diagnosis of diabetes. The description of biomarker trajectories leading to diabetes diagnosis 
could contribute to more-accurate risk prediction models that use repeated measures available for patients through 
regular check-ups.
Funding Medical Research Council (UK); Economic and Social Research Council (UK); British Heart Foundation 
(UK); Health and Safety Executive (UK); Department of Health (UK); National Institute of Health (USA); Agency for 
Health Care Policy Research (USA); the John D and Catherine T MacArthur Foundation (USA); and Academy of 
Finland (Finland).
Introduction
The current global focus on prevention of type 2 diabetes 
points out the need to understand better the 
pathophysiological changes leading to diabetes at the 
earliest possible stage.1–5 Although prediabetic 
conditions—such as impaired fasting glycaemia or 
impaired glucose tolerance—can predict the risk of 
developing diabetes, these only indicate an individual’s 
glycaemic state at a single point in time.6–9 The risk of 
developing diabetes and macrovascular complications 
might already be present at glucose concentrations below 
the current cut-oﬀ  for prediabetes.10,11
The multistage model of diabetes development 
describes an unstable period before diabetes onset.12 
Although this model is widely accepted and supported 
by several studies,13–25 important questions remain 
unanswered. An abrupt increase in fasting glucose 
might happen 1·5–3 years before diagnosis, but the exact 
trend of this increase is unknown.14,19,22 Only one study in 
Pima Indians21 described postload glucose trajectories 
before diabetes diagnosis on the basis of annual 
measurements, whereas other studies on changes in 
postload glucose are based on measurements repeated at 
least 3 years apart.14 Prospective studies13,15–18,20,23–25 have 
measured or estimated insulin sensitivity and insulin 
secretion with sophisticated methods, but generally 
describe changes as a function of the stage preceding 
diabetes rather than of time.
Because data from previous studies provide a poorly 
deﬁ ned picture of diabetes development, we aimed to 
assess the multistage model of diabetes development in 
a large population. To improve timing of screening and 
prevention, high-resolution data that describe the timing 
of early changes in glucose metabolism before occurrence 
of type 2 diabetes should be obtained. In this study from 
the longitudinal Whitehall II cohort of British civil 
servants, we characterised population trajectories of 
fasting glucose, 2-h postload glucose, insulin sensitivity, 
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and insulin secretion during 13 years of follow-up, and 
compared such trajectories between those who did and 
did not develop type 2 diabetes.
Methods
Participants and study design
All 35–55-year-old non-industrial British civil servants 
working in London oﬃ  ces (UK) of 20 departments 
were invited to participate in this study. 10 308 (6895 
men) were recruited between August, 1985, and April, 
1988  (phase 1).26 Between August, 1991, and December, 
1994 (phase 3), all participants known to be alive and 
in the country were invited to the screening clinic for 
an oral glucose tolerance test, and 6058 men and 
2758 women (85·5% of the original sample) attended. 
Screening was repeated between April, 1997, and 
August, 1999 (phase 5; 5444 men and 2385 women), 
and between October, 2002, and September, 2004 
(phase 7; 4894 men and 2074 women). Additional 
questionnaire-only phases assessed diabetes status 
between January, 1995, and July, 1996 (phase 4; 
5928 men and 2700 women), between January and 
December 2001 (phase 6; 5151 men and 2204 women), 
and between February, 2006, and June, 2007 (phase 8; 
5017 men and 2156 women). The University College 
London ethics committee reviewed and approved the 
study, and written informed consent was obtained from 
each participant.
For the analysis, when oral glucose tolerance test was 
done for the ﬁ rst time, phase 3 served as the baseline. 
After the exclusion of non-participants (n=1492) and 
individuals with prevalent diabetes at phase 3 (n=42), 
those with missing follow-up (n=552), missing ethnic-
 origin data (n=27), or serum values not suitable for 
homo eo stasis model assessment (HOMA) analysis at 
any screening visit (n=1657), the ﬁ nal sample consisted 
of 6538 participants (74% of the baseline sample). 
Participants included in the analyses were more likely to 
be white (91% vs 89%, p=0·001) and men (71% vs 63%, 
p<0·0001) than those excluded. They were also 1·8 years 
younger (95% CI 1·5 to 2·1), had 0·12 mmol/L higher 
fasting glucose (0·06 to 0·18), and 8 pmol/L higher 
fasting insu lin (4 to 11) than excluded participants. Body-
mass index did not diﬀ er (–0·16, –0·37 to 0·05 kg/m²) 
between the groups.
Of the potential 19 614 person-examinations that would 
have been generated if every participant completed all 
three screenings, 398 related to screenings after diabetes 
diagnosis and were excluded. We also excluded 
5188 person-examinations because they were not fasting 
according to WHO criteria (<8 h fasting or afternoon 
sampling); 108 because fasting plasma glucose values 
were extreme (≤3 or ≥25 mmol/L); and 2130 because 
fasting insulin values were extreme (≤20 or ≥400 pmol/L), 
exceeding the published validity ranges for HOMA 
calculations.27,28 Thus, the dataset for analysis included a 
total of 11 790 person-examinations.
Measurements
During all phases of the study, we handled samples 
according to similar standard protocols. We took venous 
blood samples in individuals who were fasting (≥8 h of 
fasting) before undergoing a standard 2-h oral glucose 
tolerance test. Glucose samples were drawn into ﬂ uoride 
monovette tubes and insulin samples into native tubes, 
which were centrifuged on site within 1 h. Plasma or 
serum was immediately removed from the monovette 
tubes, and moved into microtubes and stored at –70°C. 
We measured blood glucose with the glucose oxidase 
method29 on YSI model 23A glucose analyser (phase 3, 
mean coeﬃ  cient of variation [CV] 2·9–3·3%)30 and YSI 
model 2300 STAT PLUS analyser (phases 5 and 7, mean 
CV 1·4–3·1%)31 (YSI Corporation, Yellow Springs, OH, 
USA), and serum insulin with an in-house human 
insulin radioimmunoassay (phase 3, mean CV 7%)32 and 
a DAKO insulin ELISA kit (DakoCytomation Ltd, Ely, 
UK) (phases 5 and 7, mean CV 4·2–9·3%).33 We 
calculated HOMA insulin sensitivity and HOMA β-cell 
function on the basis of model-derived estimates (rather 
than linear approximations) with the HOMA2 calculator 
version 2.2.27,28
Diabetes was deﬁ ned by a fasting glucose of 
7·0 mmol/L or more, or a 2-h postload glucose of 
11·1 mmol/L or more.34,35 During the duration of 
follow-up (median 9·7 years; interquartile range [IQR] 
7·9–14·2), we diagnosed 505 diabetes cases mostly on 
the basis of 75 g oral glucose tolerance test (248 cases, 
49%), except for those reporting doctor-diagnosed 
diabetes (179 cases, 35%), or use of diabetes medication 
(78 cases, 15%) at screening or additional questionnaire 
phases.
Statistical analysis
Statistical analyses were undertaken using SPSS version 
14.0 statistical software. We divided participants into two 
groups: those who developed and those who did not 
develop diabetes during the follow-up period. The 
observation period started at the date of diagnosis (year 0) 
for those who became diabetic, and at the last screening 
or questionnaire phase for non-diabetics. Participants 
were then traced backwards to their ﬁ rst clinical 
screening. Data at each phase during this retrospective 
observation period were collated to build trajectories for 
each outcome (fasting glucose, 2-h glucose, HOMA 
insulin sensitivity, and HOMA β-cell function). For 
example, a participant who reported diagnosed diabetes 
at phase 8 has his time 0 at the midpoint of phases 7 
and 8 (estimated time of diagnosis), and has three 
measurements: one at phase 7, about 1 year before the 
event; another at phase 5, about 6 years before the event; 
and another at phase 3, about 11 years before the event. 
As shown in ﬁ gures 1 and 2, measurements were well 
distributed throughout the 13-year time window of the 
study because of the variation in screening dates and 
dates of diabetes diagnosis.
For more on HOMA2 calculator 
see http://www.dtu.ox.ac.uk/
index.php?maindoc=/homa/
index.php
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In a preliminary analysis, we plotted these trajectories 
as a function of time, and ﬁ tted non-parametric curves 
with locally weighted scatterplot smoother for graphical 
representation. We then used multilevel longitudinal 
modelling to estimate trajectories of fasting glucose, 2-h 
glucose, HOMA insulin sensitivity, and HOMA β-cell 
function in diabetics before diagnosis and in 
non-diabetics before last screening.36 Data were organised 
so that repeated measurements of the three screening 
phases (ie, person-examinations) were nested within 
participants and the non-independence of the 
person-examinations (the same individuals contributed 
more than one person-examination in the dataset) was 
taken into account in estimating standard errors. We 
modelled diﬀ erences in trajectories between diabetics 
and non-diabetics with either a linear or non-linear 
growth model.
We treated observation time as one period (a non-
piecewise approach) or two distinct periods (a piecewise 
approach).37 In the latter approach, we created two time 
variables: a continuous variable centered at the start of 
the second period (time=0) and a dummy variable 
indicating the period (0=1st period and 1=2nd period). 
We ﬁ rst established the most parsimonious model for 
each centring point (from –9 to 0) and then chose the 
centering point that had the lowest information criteria 
for the ﬁ nal model.
All analyses were adjusted for age, sex, ethnic origin, 
and study phase. To provide ﬁ gures adjusted for baseline 
characteristics, trajectories were ﬁ tted for a hypothetical 
population of 71% male, 91% white individuals 63 years 
old at the end of follow-up. Finally, we checked how the 
models matched the non-parametric scatterplot curves 
from the preliminary analysis (webappendix p 5) and ran 
some sensitivity analyses to test whether our ﬁ ndings 
were robust (webappendix pp 2–4). Statistical signiﬁ cance 
was inferred at a two-tailed p<0·05.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Incident 
diabetes 
(N=505)
Non-diabetics 
(N=6033)
p value
Age (years) 53·1 (6·6) 52·6 (7·1) 0·12
Male 66% 71% 0·029
White 80% 92% <0·0001
Body-mass index (kg/m²) 28·18 (4·99) 25·60 (3·63) <0·0001
Fasting glucose (mmol/L) 5·71 (0·91) 5·21 (0·47) <0·0001
2-h postload glucose 
(mmol/L)
7·06 (2·48) 5·38 (1·42) <0·0001
Fasting insulin (pmol/L) 73 (30) 47 (30) <0·0001
2-h postload insulin 
(pmol/L)
473 (351) 259 (222) <0·0001
HOMA2-%S 103·4 (58·8%) 145·1% (63·2%) <0·0001
HOMA2-%B 88·5 (39·0%) 78·4% (30·3%) <0·0001
Data are mean (SD) or percentage. Comparisons were done with two-sample 
t tests or Fisher’s exact tests, as appropriate. HOMA2-%S and HOMA2-%B were 
calculated using HOMA2 calculator version 2.2 (Diabetes Trials Unit, University of 
Oxford, Oxford, UK).27,28 HOMA2-%S=homoeostasis model assessment insulin 
sensitivity. HOMA2-%B=homoeostasis model assessment β-cell function.
Table 1: Baseline characteristics of incident diabetes cases and 
non-diabetics
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Figure 1: Fasting (A) and 2-h postload (B) glucose trajectories before diagnosis of diabetes or the end of 
follow-up
Numbers are 505 incident diabetes cases and 6033 non-diabetics. Time 0 is diagnosis for incident diabetes cases 
or end of follow-up for non-diabetics. Multilevel longitudinal modelling was done using linear growth model for 
non-diabetic and piecewise approach, including cubic terms for time, for incident diabetic individuals with oral 
glucose tolerance test fasting glucose (A) and 2-h glucose (B) as outcomes. Analysis was adjusted for age, sex, 
ethnic origin, and study phase. Estimations were done for a hypothetical population consisting of 71% male, 
91% white individuals aged 63 years at time 0 years. Error bars show 95% CI for the ﬁ xed eﬀ ects. Tables show the 
number of measurements for each year at and before diabetes diagnosis or the end of follow-up.
See Online for webappendix
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Results
The 505 incident diabetic participants contributed a 
total of 801 fasting measurements, and the 6033 non-
 diabetics contributed 10 989. The mean age did not diﬀ er 
between groups (table 1). As expected, incident diabetic 
cases were less likely to be men and white, and had 
higher body-mass index than non-diabetics (table 1). At 
baseline, they also had higher fasting and postload 
plasma glucose, fasting and postload insulin, and 
HOMA β-cell function, and a lower HOMA insulin 
sensitivity (all p<0·0001).
Non-diabetics had a slight increase of fasting plasma 
glucose over time (mean [SE] 0·004 mmol/L [0·001] per 
year), with fasting plasma glucose concentrations of 
5·26 mmol/L (0·008) 13 years before diagnosis and 
5·31 mmol/L (0·010) at the end of follow-up (ﬁ gure 1A 
and table 2). For incident diabetes cases, we saw a linear 
trend of fasting plasma glucose from 13 years to 3 years 
before diagnosis but with a steeper slope than non-
diabetics (slope diﬀ erence 0·028 mmol/L [0·007] per 
year). Fasting plasma glucose values were 5·47 mmol/L 
[0·04] 13 years before diagnosis and 5·79 mmol/L [0·04] 
at 3 years before diagnosis (ﬁ gure 1A). In the last 3 years 
before diagnosis, the trajectory followed a quadratic 
curve reaching 7·40 mmol/L (0·04) at the time of 
diagnosis.
In non-diabetics, 2-h postload glucose increased from 
5·11 mmol/L (0·024) to 5·77 mmol/L (0·098) during the 
13 years of assessment, with a slope of 0·051 mmol/L 
(0·007) per year (ﬁ gure 1B and table 2). The slopes were 
not signiﬁ cantly diﬀ erent between the diabetes and the 
non-diabetes groups from 13 to 6 years before the end of 
follow-up, but diabetes cases had a 0·99 mmol/L (0·09) 
higher glucose value throughout this period.
From the 6 years before diagnosis to the end of follow-up, 
postload glucose concentrations of incident diabetes cases 
followed a cubic trajectory with a ﬂ at part from 5 to 3 years 
before diagnosis. The diﬀ erence of postload glucose 
concentrations was about 1·5 times larger between 
incident cases and non-diabetics during this period than 
in the preceding period from 13 to 6 years before diagnosis 
(ﬁ gure 1B). Diabetes cases had a rapid increase of glucose 
concentrations from 2 years before diagnosis onward 
(from 7·60 mmol/L [0·15] to 11·90 mmol/L [0·13]).
From 13 to 5 years before the end of follow-up, HOMA 
insulin sensitivity decreased linearly with the same slope 
of 1·11% (0·30) per year in diabetes cases and 
non-diabetics (ﬁ gure 2A and table 2). Those with incident 
diabetes had a 34·2% (3·1) lower insulin sensitivity 
during this period. In the 5 years before diagnosis, 
HOMA insulin sensitivity decreased with a steeper slope 
in diabetes cases than in non-diabetics (diﬀ erence in 
slopes per year 2·76% [0·85]), reaching 86·7% (4·7) at 
the end of follow-up (ﬁ gure 2A).
The calculated insulin secretion (HOMA β-cell 
function) did not change for either participant group 
between 13 and 4 years before the end of follow-up (ﬁ gure 
2B and table 2). However, HOMA β-cell function of 
85·0% (1·5) in diabetes cases was, on average, 10·4% 
(1·5) higher than that in non-diabetics. During the 4 years 
before diagnosis, HOMA β-cell function values of 
diabetes cases followed a negative quadratic trajectory 
with a steep increase to 92·6% (2·5) between years 4 and 
3 before diagnosis, followed by a steep decrease to 62·4% 
(2·3) between 3 years before diagnosis and end of 
follow-up (ﬁ gure 2A).
The models for trajectories of fasting and postload 
glucose, HOMA insulin sensitivity, and HOMA β-cell 
function (table 2) were supported in several sensitivity 
analyses: in an extended study population, including also 
those with 5–8 h of fasting (n=7148, sensitivity analysis 1); 
in a subgroup of participants with no missing data before 
diagnosis (diabetics) or phase 8 (non-diabetics) (n=1332, 
sensitivity analysis 2); and when the timing of diabetes 
was set to the midpoint between date of diagnosis and the 
preceding examination to calculate the onset of disease 
(n=6290, sensitivity analysis 3) (webappendix p 2). Adjust-
ment for time-varying body-mass index attenuated the 
diﬀ erence in insulin sensitivity between diabetics and 
non-diabetics, but it had little eﬀ ect on the diﬀ erences in 
trajectories between groups (webappendix p 4).
Discussion
We describe the 13-year trajectories of fasting and postload 
blood glucose, insulin sensitivity, and insulin secretion 
until diabetes diagnosis in a large middle-aged, 
metabolically healthy population at baseline. All changes 
in metabolic measures in individuals who did not develop 
diabetes were well described by linear trajectories (modest 
rises for fasting and postload glucose, steady values for 
insulin secretion, and slight falls for insulin sensitivity). 
In individuals who developed diabetes, the levels of fasting 
and postload glucose and insulin secretion were higher, 
and insulin sensitivity was lower, than those in controls as 
Fasting glucose 
(mmol/L)
2-h postload 
glucose (mmol/L)
HOMA2-%S HOMA2-%B
Time (per year) 0·004† (0·001) 0·051† (0·007) –1·11%‡ (0·30) ··
Case 0·50† (0·04) 0·99† (0·09) –34·21%† (3·15) 10·45%† (1·55)
Case×time 0·028‡ (0·007) ·· ·· ··
Case×time×2nd period –0·27¶ (0·09) 1·54† (0·22) –2·76%¶ (0·85) 12·13%‡ (3·21)
Case×time²×2nd period 0·26† (0·027) –0·75† (0·10) ·· –4·44%† (0·84)
Case×time³×2nd period ·· 0·11† (0·01) ·· ··
Data are regression coeﬃ  cient (SE). Time=a continuous variable centred (time=0) at 3 years before diagnosis or the 
end of follow-up for fasting glucose, 6 years for postload glucose, 5 years for HOMA2-%S, and 4 years for HOMA2-%B. 
2nd period=a dummy variable: 1 for positive values in the time variable and 0 for non-positive values. Case=incident 
diabetes case. HOMA2-%S=homoeostasis model assessment insulin sensitivity. HOMA2-%B=homoeostasis model 
assessment β-cell function. *Trajectories in 505 incident diabetes cases were compared with those in 6033 non-diabetics. 
Multilevel longitudinal modelling used a linear growth model for non-diabetic and a piecewise approach, including cubic 
terms for time, for incident diabetic individuals with oral glucose tolerance test fasting glucose, 2-h glucose, HOMA2-%S, 
and HOMA2-%B as outcomes. Data were adjusted for age, sex, ethnic origin, and study phase. Only models with the 
lowest information criteria are shown for each outcome. †p<0·0001. ‡p<0·001. ¶p<0·01.
Table 2: Fixed eﬀ ects for multilevel models of change for fasting glucose, 2-h postload glucose, HOMA 
insulin sensitivity, and HOMA β-cell function before diagnosis of diabetes or the end of follow-up*
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early as 13 years before diagnosis. In incident diabetes 
cases, linear increases in fasting and postload glucose 
were followed by a rapid increase in levels 6 to 3 years 
before diagnosis. HOMA insulin sensitivity showed a 
steep decrease during the last 5 years before diagnosis and 
HOMA β-cell function increased between years 4 and 3 
before diagnosis, and then decreased until diagnosis.
Our ﬁ ndings support a multistage model of diabetes 
aetiology:12 a long compensatory period, when insulin 
secretion increases to compensate insulin resistance 
without any major changes in glucose values; a stable 
adaptation, when β-cell mass is decreasing in spite of 
β-cell adaptation; and a transient unstable period with a 
rapid rise of glucose to overt diabetes. Our results suggest 
a stable adaptation when fasting blood glucose values 
increase linearly with a steeper slope in people who later 
develop diabetes than in healthy participants, whereas 
postload glucose increases in a similar way to that of 
controls. The observed accelerated rises ﬁ t with the 
unstable period leading to diabetes.
Our study is in agreement with several other studies14,19,22 
that showed an abrupt increase in fasting glucose values 
1·5 to 3 years before diagnosis of diabetes. We observed an 
increase of 0·02–0·8 mmol/L in glucose per year across 
the whole 13-year observation period before diabetes 
diagnosis; this is in agreement with annual increases in 
glucose reported previously (range 0·4–1·2 mmol/L),14,19,22 
and conﬁ rmed previous observations about rapid increases 
in fasting glucose in impaired glucose tolerance or when 
β-cell dysfunction is present.25,38 However, none of these 
studies did a continuous prediction of fasting glucose 
similar to our study, and most of them were based on fewer 
cases (<200) and a shorter follow-up period.
Our ﬁ ndings on postload glucose trajectories are similar 
to those in smaller-scale studies. A study including three 
data collections showed 5–6 mmol/L increase of postload 
glucose in the 7 years preceding diabetes.14 In younger 
Pima Indians (mean age at diagnosis 46 years), a linear 
increase of postload glucose up to 4–8 years before diabetes 
diagnosis with a similar slope was also found.21 Our results 
conﬁ rm ﬁ ndings of the abrupt increase of postload glucose 
and extend it to a broader, mostly white, population.21
Low insulin sensitivity seems to be a prerequisite for 
incident diabetes.13,16–18,20,24,25 Scarce evidence exists on the 
association between insulin sensitivity and development 
of impaired glucose tolerance.16,17,20,24 The decrease in 
insulin sensitivity in those who develop impaired glucose 
tolerance does not diﬀ er from that observed in people 
who remain normoglycaemic, but is much smaller than 
in those who develop incident diabetes.16 This is in 
agreement with our ﬁ ndings that show that the decreased 
insulin sensitivity before the 4 years preceding diabetes 
diagnosis was similar to that in normoglycaemic controls, 
but a steeper decrease in insulin sensitivity was seen 
during the few years immediately before diagnosis.
The role of insulin secretion and β-cell function as 
predictors of type 2 diabetes is unclear. Most studies report 
no association between insulin secretion and dia-
betes,13,16,19,24,39 whereas the association of low disposition 
index with diabetes is well established.13,16,17,20,24 Furthermore, 
evidence exists of a higher insulin secretion in impaired 
glucose tolerance than in normal glucose tolerance, and a 
lower insulin secretion in diabetes than in impaired 
glucose tolerance, at least in non-Asian populations.15,23
Our ﬁ ndings suggest that part of the explanation for 
inconsistencies in the above described results might arise 
from diﬀ erences in time frames between studies. High 
values of insulin secretion might be associated with 
increased risk of type 2 diabetes if measured years or 
Figure 2: Homoeostasis model assessment (HOMA) insulin sensitivity (A) and HOMA β-cell function 
trajectories (B) before diagnosis of diabetes or the end of follow-up
Numbers are 505 incident diabetes cases and 6033 non-diabetics. Time 0 is diagnosis for incident diabetes cases or 
end of follow-up for non-diabetics. Multilevel longitudinal modelling was done using linear growth model for 
non-diabetic and non-piecewise or piecewise approach, including linear or quadratic terms for time, for incident 
diabetic individuals with HOMA2-%S (A) and HOMA2-%B (B) as outcomes. Analysis was adjusted for age, sex, ethnic 
origin, and study phase. Estimations were done for a hypothetical population consisting of 71% male, 91% white 
individuals aged 63 years at time 0 years. Error bars show 95% CI for the ﬁ xed eﬀ ects. Tables show the number of 
measurements for each year at and before diabetes diagnosis or the end of follow-up. HOMA2-%S=homoeostasis 
model assessment insulin sensitivity. HOMA2-%B=homoeostasis model assessment β-cell function.
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decades before diagnosis, but low values predict the 
short-term diabetes risk. This is consistent with 
longitudinal studies reporting modest changes in acute 
insulin response or even in disposition index during the 
transition from normal to impaired glucose tolerance, but 
substantial decreases during further progression to 
diabetes.16,17,24 Further research is needed to assess whether 
timing of the changes in insulin secretion, insulin 
sensitivity, and fasting and postload glucose points to 
causal relations between these indexes.
Our study beneﬁ ts from a well phenotyped and well 
described occupational cohort of people and diagnosis of 
incident diabetes based on oral glucose tolerance test 
using the current deﬁ nition of the disease.26,34 We applied 
a sophisticated approach for data analysis taking into 
account the inter-relation between repeated measurements 
from the same individual at diﬀ erent timepoints. The 
long follow-up time provided a unique opportunity to 
describe diﬀ erent periods of prediabetes status according 
to trajectories based on piecewise modelling.
The inclusion of the diagnostic glucose value in the 
analysis might be criticised because any diagnostic 
threshold would produce a rapid rise in the mean in those 
who exceed this threshold.21 To overcome this issue, we 
reﬁ tted the multilevel models excluding the diagnostic 
value from the analysis. These models produced similar 
trajectories to those presented here. Furthermore, several 
other reports14,19,21,22 suggest a rapid rise in fasting and 2-h 
glucose values, and the modelling of individual growth 
curves of postload glucose also supports the presence of a 
rapid rise at the time of diagnosis.21 These ﬁ ndings 
suggest that we might have detected a genuine 
prediagnosis trajectory in glucose values.
We used measures of HOMA insulin sensitivity and 
insulin resistance, which are well accepted in the published 
literature. HOMA insulin sensitivity is extensively 
validated against the gold standard clamp and minimal 
model methods.28,40 However, the calculated insulin 
secretion is less widely used.28,40,41 Because HOMA uses 
fasting values for estimation, it mostly describes hepatic 
insulin resistance and steady-state insulin secretion. 
Although hepatic insulin resistance is strongly correlated 
with muscle and fat insulin resistance, the steady-state 
insulin secretion is a late marker of β-cell dysfunction and 
shows only a moderate correlation with the most sensitive 
measures of the ﬁ rst-phase insulin secretion.28,42 Therefore, 
our ﬁ ndings might be an underestimation of the timing 
of early β-cell decompensation.
We did not use disposition index to describe changes in 
glucose metabolism with a single parameter because its 
calculation based on HOMA values has several theoretical 
issues and the compensation described by it could be 
incomplete even in normal glucose-tolerant individuals.42–44
Data from almost 20 000 blood glucose values provide 
an excellent power to assess general trajectories in a 
piecewise model based on between-subject and within-
subject comparisons. The proposed trajectories give a 
good description of the events leading to diabetes. 
However, the restricted number of repeated observations 
for each participant (maximum three) means that 
individual diﬀ erences in trajectories could not be identiﬁ ed 
in these data and should be studied in the future.
Of the baseline population, 26% was excluded because 
of missing data, extreme glucose or insulin values, or 
prevalent diabetes. Selection bias is an unlikely explana-
tion for our results because comparisons of parti cipants 
included and excluded from analyses revealed modest 
diﬀ erences, although statistical sig niﬁ cance was often 
reached because of large numbers. In the main analysis, 
we excluded individuals who had fasted less than 8 h, but 
sensitivity analyses showed that inclusion of those who 
had fasted 5–8 h (the Whitehall II protocol) had little 
eﬀ ect on the ﬁ ndings. Furthermore, the main ﬁ ndings 
were replicated in a subgroup with no missing data, 
suggesting that missing data are an unlikely source of 
bias in this study.
The description of biomarker trajectories leading to 
diabetes diagnosis could contribute to future attempts of 
building more-accurate risk prediction models that use 
the wealth of repeated measures available for patients 
through regular check -ups. These models might give an 
indication of which trajectory best describes an 
individual’s results. We anticipate that these models will 
have a better prediction than those that use only the most 
recent glucose measurements.
Our ﬁ ndings show various opportunities for screening 
and prevention. Although most prevention studies focused 
on prediabetic people, our ﬁ ndings suggest that people 
with prediabetes are already on the steep part of the 
glucose trajectory. We hypothesise that prevention would 
be more eﬀ ective before this unstable period, but more 
research is needed to identify people at this stage of 
disease development. If a person could be kept on the 
linear part of the fasting glucose (or postload glucose21) 
trajectory, the onset of diabetes might be substantially 
delayed. Further research is needed to conﬁ rm or refute 
these hypotheses.
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